b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">31503264</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>07</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>07</Month>\n            <Day>31</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Print">1027-6661</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>25</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery</Title>\n                <ISOAbbreviation>Angiol Sosud Khir</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>[Antithrombotic therapy after venous stenting].</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>183-187</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.33529/ANGID2019302</ELocationID>\n            <Abstract>\n                <AbstractText>Presented herein is a literature review considering the problems of using antithrombotic therapy after venous stenting. Described herein are the literature data according to which the authors give preference to anticoagulant therapy (low-molecular-weight heparins, vitamin K antagonists, direct oral anticoagulants). This is followed by considering the problems of duration of treatment depending on various clinical situations. According to the presented data, the problem of prescribing disaggregants in a combination with anticoagulants after stenting of veins remains disputable, finding however many supporters. Analysed in the article are the results of the first International Delphi Consensus dedicated to antithrombotic therapy after venous stenting. Participating in the study were 106 independent experts practicing stenting in 78 centres of 28 countries of the world. Nonthrombotic iliac vein lesions, having appeared as May-Thurner syndrome due to extravasal compression and residual obstruction after thrombolysis, as well as the presence of postthrombotic syndrome were the main \'scenarios\' for our study. The study resulted in working out provisions considering the policy of antithrombotic therapy in various obstructive lesions of deep veins. According to the presented data, anticoagulant therapy is preferable during 6-12 months after stenting in nonthrombotic iliac vein lesions. Low-molecular-weight heparins appear to be a method of choice in treatment during the first 2-6 weeks. Life-long administration of anticoagulants is recommended after multiple deep vein thromboses. Discontinuation of anticoagulants after 6-12 months is indicated after venous stenting in one episode of deep vein thrombosis. No consensus was achieved regarding the role of prolonged disaggregant therapy. Underlined in the article is the importance of a meticulous individual approach to choosing optimal policy of antithrombotic therapy and determining therapeutic policy together with a haematologist.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ignatyev</LastName>\n                    <ForeName>I M</ForeName>\n                    <Initials>IM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Cardiovascular and Endovascular Surgery, Kazan State Medical University of the RF Ministry of Public Health, Kazan, Russia.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>rus</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <VernacularTitle>Antitromboticheskaia terapiia posle venoznogo stentirovaniia.</VernacularTitle>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Russia (Federation)</Country>\n            <MedlineTA>Angiol Sosud Khir</MedlineTA>\n            <NlmUniqueID>9604504</NlmUniqueID>\n            <ISSNLinking>1027-6661</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D005268" MajorTopicYN="Y">Femoral Vein</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005343" MajorTopicYN="Y">Fibrinolytic Agents</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007084" MajorTopicYN="N">Iliac Vein</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010690" MajorTopicYN="N">Phlebography</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015607" MajorTopicYN="Y">Stents</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014654" MajorTopicYN="N">Vascular Patency</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <OtherAbstract Type="Publisher" Language="rus">\n            <AbstractText>\xd0\x9f\xd1\x80\xd0\xb5\xd0\xb4\xd1\x81\xd1\x82\xd0\xb0\xd0\xb2\xd0\xbb\xd0\xb5\xd0\xbd \xd0\xbe\xd0\xb1\xd0\xb7\xd0\xbe\xd1\x80 \xd0\xbb\xd0\xb8\xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd1\x82\xd1\x83\xd1\x80\xd1\x8b, \xd0\xb2 \xd0\xba\xd0\xbe\xd1\x82\xd0\xbe\xd1\x80\xd0\xbe\xd0\xbc \xd1\x80\xd0\xb0\xd1\x81\xd1\x81\xd0\xbc\xd0\xb0\xd1\x82\xd1\x80\xd0\xb8\xd0\xb2\xd0\xb0\xd1\x8e\xd1\x82\xd1\x81\xd1\x8f \xd0\xb2\xd0\xbe\xd0\xbf\xd1\x80\xd0\xbe\xd1\x81\xd1\x8b \xd0\xbf\xd1\x80\xd0\xb8\xd0\xbc\xd0\xb5\xd0\xbd\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xbe\xd0\xb9 \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd0\xb8 \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd0\xb2\xd0\xb5\xd0\xbd\xd0\xbe\xd0\xb7\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd1\x81\xd1\x82\xd0\xb5\xd0\xbd\xd1\x82\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd1\x8f. \xd0\x9f\xd1\x80\xd0\xb8\xd0\xb2\xd0\xbe\xd0\xb4\xd1\x8f\xd1\x82\xd1\x81\xd1\x8f \xd0\xbb\xd0\xb8\xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd1\x82\xd1\x83\xd1\x80\xd0\xbd\xd1\x8b\xd0\xb5 \xd0\xb4\xd0\xb0\xd0\xbd\xd0\xbd\xd1\x8b\xd0\xb5, \xd1\x81\xd0\xbe\xd0\xb3\xd0\xbb\xd0\xb0\xd1\x81\xd0\xbd\xd0\xbe \xd0\xba\xd0\xbe\xd1\x82\xd0\xbe\xd1\x80\xd1\x8b\xd0\xbc \xd0\xb0\xd0\xb2\xd1\x82\xd0\xbe\xd1\x80\xd1\x8b \xd0\xbe\xd1\x82\xd0\xb4\xd0\xb0\xd1\x8e\xd1\x82 \xd0\xbf\xd1\x80\xd0\xb5\xd0\xb4\xd0\xbf\xd0\xbe\xd1\x87\xd1\x82\xd0\xb5\xd0\xbd\xd0\xb8\xd0\xb5 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb0\xd0\xb3\xd1\x83\xd0\xbb\xd1\x8f\xd0\xbd\xd1\x82\xd0\xbd\xd0\xbe\xd0\xb9 \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd0\xb8 (\xd0\xbd\xd0\xb8\xd0\xb7\xd0\xba\xd0\xbe\xd0\xbc\xd0\xbe\xd0\xbb\xd0\xb5\xd0\xba\xd1\x83\xd0\xbb\xd1\x8f\xd1\x80\xd0\xbd\xd1\x8b\xd0\xb5 \xd0\xb3\xd0\xb5\xd0\xbf\xd0\xb0\xd1\x80\xd0\xb8\xd0\xbd\xd1\x8b, \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb0\xd0\xb3\xd0\xbe\xd0\xbd\xd0\xb8\xd1\x81\xd1\x82\xd1\x8b \xd0\xb2\xd0\xb8\xd1\x82\xd0\xb0\xd0\xbc\xd0\xb8\xd0\xbd\xd0\xb0 \xd0\x9a, \xd0\xbf\xd1\x80\xd1\x8f\xd0\xbc\xd1\x8b\xd0\xb5 \xd0\xbe\xd1\x80\xd0\xb0\xd0\xbb\xd1\x8c\xd0\xbd\xd1\x8b\xd0\xb5 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb0\xd0\xb3\xd1\x83\xd0\xbb\xd1\x8f\xd0\xbd\xd1\x82\xd1\x8b). \xd0\xa0\xd0\xb0\xd1\x81\xd1\x81\xd0\xbc\xd0\xb0\xd1\x82\xd1\x80\xd0\xb8\xd0\xb2\xd0\xb0\xd1\x8e\xd1\x82\xd1\x81\xd1\x8f \xd0\xb2\xd0\xbe\xd0\xbf\xd1\x80\xd0\xbe\xd1\x81\xd1\x8b \xd0\xb4\xd0\xbb\xd0\xb8\xd1\x82\xd0\xb5\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd1\x81\xd1\x82\xd0\xb8 \xd0\xbb\xd0\xb5\xd1\x87\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xb2 \xd0\xb7\xd0\xb0\xd0\xb2\xd0\xb8\xd1\x81\xd0\xb8\xd0\xbc\xd0\xbe\xd1\x81\xd1\x82\xd0\xb8 \xd0\xbe\xd1\x82 \xd1\x80\xd0\xb0\xd0\xb7\xd0\xbb\xd0\xb8\xd1\x87\xd0\xbd\xd1\x8b\xd1\x85 \xd0\xba\xd0\xbb\xd0\xb8\xd0\xbd\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xb8\xd1\x85 \xd1\x81\xd0\xb8\xd1\x82\xd1\x83\xd0\xb0\xd1\x86\xd0\xb8\xd0\xb9. \xd0\xa1\xd0\xbe\xd0\xb3\xd0\xbb\xd0\xb0\xd1\x81\xd0\xbd\xd0\xbe \xd0\xbf\xd1\x80\xd0\xb5\xd0\xb4\xd1\x81\xd1\x82\xd0\xb0\xd0\xb2\xd0\xbb\xd0\xb5\xd0\xbd\xd0\xbd\xd1\x8b\xd0\xbc \xd0\xb4\xd0\xb0\xd0\xbd\xd0\xbd\xd1\x8b\xd0\xbc \xd0\xb2\xd0\xbe\xd0\xbf\xd1\x80\xd0\xbe\xd1\x81 \xd0\xbd\xd0\xb0\xd0\xb7\xd0\xbd\xd0\xb0\xd1\x87\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xb4\xd0\xb5\xd0\xb7\xd0\xb0\xd0\xb3\xd1\x80\xd0\xb5\xd0\xb3\xd0\xb0\xd0\xbd\xd1\x82\xd0\xbe\xd0\xb2 \xd0\xb2 \xd1\x81\xd0\xbe\xd1\x87\xd0\xb5\xd1\x82\xd0\xb0\xd0\xbd\xd0\xb8\xd0\xb8 \xd1\x81 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb0\xd0\xb3\xd1\x83\xd0\xbb\xd1\x8f\xd0\xbd\xd1\x82\xd0\xb0\xd0\xbc\xd0\xb8 \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd1\x81\xd1\x82\xd0\xb5\xd0\xbd\xd1\x82\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xb2\xd0\xb5\xd0\xbd \xd0\xbe\xd1\x81\xd1\x82\xd0\xb0\xd0\xb5\xd1\x82\xd1\x81\xd1\x8f \xd0\xb4\xd0\xb8\xd1\x81\xd0\xba\xd1\x83\xd1\x82\xd0\xb0\xd0\xb1\xd0\xb5\xd0\xbb\xd1\x8c\xd0\xbd\xd1\x8b\xd0\xbc, \xd1\x85\xd0\xbe\xd1\x82\xd1\x8f \xd0\xb8 \xd0\xbd\xd0\xb0\xd1\x85\xd0\xbe\xd0\xb4\xd0\xb8\xd1\x82 \xd0\xbd\xd0\xb5\xd0\xbc\xd0\xb0\xd0\xbb\xd0\xbe \xd1\x81\xd1\x82\xd0\xbe\xd1\x80\xd0\xbe\xd0\xbd\xd0\xbd\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb2. \xd0\x92 \xd1\x81\xd1\x82\xd0\xb0\xd1\x82\xd1\x8c\xd0\xb5 \xd0\xbf\xd1\x80\xd0\xbe\xd0\xb0\xd0\xbd\xd0\xb0\xd0\xbb\xd0\xb8\xd0\xb7\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd1\x8b \xd1\x80\xd0\xb5\xd0\xb7\xd1\x83\xd0\xbb\xd1\x8c\xd1\x82\xd0\xb0\xd1\x82\xd1\x8b \xd0\xbf\xd0\xb5\xd1\x80\xd0\xb2\xd0\xbe\xd0\xb3\xd0\xbe \xd0\xbc\xd0\xb5\xd0\xb6\xd0\xb4\xd1\x83\xd0\xbd\xd0\xb0\xd1\x80\xd0\xbe\xd0\xb4\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd0\xba\xd0\xbe\xd0\xbd\xd1\x81\xd0\xb5\xd0\xbd\xd1\x81\xd1\x83\xd1\x81\xd0\xb0 Delphi, \xd0\xbf\xd0\xbe\xd1\x81\xd0\xb2\xd1\x8f\xd1\x89\xd0\xb5\xd0\xbd\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xbe\xd0\xb9 \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd0\xb8 \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd0\xb2\xd0\xb5\xd0\xbd\xd0\xbe\xd0\xb7\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd1\x81\xd1\x82\xd0\xb5\xd0\xbd\xd1\x82\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd1\x8f. \xd0\x92 \xd0\xb8\xd1\x81\xd1\x81\xd0\xbb\xd0\xb5\xd0\xb4\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd0\xb8 \xd0\xbf\xd1\x80\xd0\xb8\xd0\xbd\xd0\xb8\xd0\xbc\xd0\xb0\xd0\xbb\xd0\xb8 \xd1\x83\xd1\x87\xd0\xb0\xd1\x81\xd1\x82\xd0\xb8\xd0\xb5 106 \xd0\xbd\xd0\xb5\xd0\xb7\xd0\xb0\xd0\xb2\xd0\xb8\xd1\x81\xd0\xb8\xd0\xbc\xd1\x8b\xd1\x85 \xd1\x8d\xd0\xba\xd1\x81\xd0\xbf\xd0\xb5\xd1\x80\xd1\x82\xd0\xbe\xd0\xb2, \xd0\xbf\xd1\x80\xd0\xb0\xd0\xba\xd1\x82\xd0\xb8\xd0\xba\xd1\x83\xd1\x8e\xd1\x89\xd0\xb8\xd1\x85 \xd1\x81\xd1\x82\xd0\xb5\xd0\xbd\xd1\x82\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd0\xb5 \xd0\xb2 78 \xd1\x86\xd0\xb5\xd0\xbd\xd1\x82\xd1\x80\xd0\xb0\xd1\x85 28 \xd1\x81\xd1\x82\xd1\x80\xd0\xb0\xd0\xbd \xd0\xbc\xd0\xb8\xd1\x80\xd0\xb0. \xd0\x9d\xd0\xb5\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xb8\xd0\xb5 \xd0\xbf\xd0\xbe\xd1\x80\xd0\xb0\xd0\xb6\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xbf\xd0\xbe\xd0\xb4\xd0\xb2\xd0\xb7\xd0\xb4\xd0\xbe\xd1\x88\xd0\xbd\xd1\x8b\xd1\x85 \xd0\xb2\xd0\xb5\xd0\xbd, \xd0\xba\xd0\xbe\xd1\x82\xd0\xbe\xd1\x80\xd1\x8b\xd0\xb5 \xd0\xbf\xd1\x80\xd0\xbe\xd1\x8f\xd0\xb2\xd0\xb8\xd0\xbb\xd0\xb8\xd1\x81\xd1\x8c \xd0\xb2 \xd0\xb2\xd0\xb8\xd0\xb4\xd0\xb5 \xd1\x81\xd0\xb8\xd0\xbd\xd0\xb4\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb0 May\xe2\x80\x93Thurner \xd0\xb2\xd1\x81\xd0\xbb\xd0\xb5\xd0\xb4\xd1\x81\xd1\x82\xd0\xb2\xd0\xb8\xd0\xb5 \xd1\x8d\xd0\xba\xd1\x81\xd1\x82\xd1\x80\xd0\xb0\xd0\xb2\xd0\xb0\xd0\xb7\xd0\xb0\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd0\xb9 \xd0\xba\xd0\xbe\xd0\xbc\xd0\xbf\xd1\x80\xd0\xb5\xd1\x81\xd1\x81\xd0\xb8\xd0\xb8 \xd0\xb8 \xd1\x80\xd0\xb5\xd0\xb7\xd0\xb8\xd0\xb4\xd1\x83\xd0\xb0\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd0\xb9 \xd0\xbe\xd0\xb1\xd1\x81\xd1\x82\xd1\x80\xd1\x83\xd0\xba\xd1\x86\xd0\xb8\xd0\xb8 \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd0\xbb\xd0\xb8\xd0\xb7\xd0\xb8\xd1\x81\xd0\xb0, \xd0\xb0 \xd1\x82\xd0\xb0\xd0\xba\xd0\xb6\xd0\xb5 \xd0\xbd\xd0\xb0\xd0\xbb\xd0\xb8\xd1\x87\xd0\xb8\xd0\xb5 \xd0\xbf\xd0\xbe\xd1\x81\xd1\x82\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xbe\xd0\xb3\xd0\xbe \xd1\x81\xd0\xb8\xd0\xbd\xd0\xb4\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb0 \xd1\x8f\xd0\xb2\xd0\xb8\xd0\xbb\xd0\xb8\xd1\x81\xd1\x8c \xd0\xbe\xd1\x81\xd0\xbd\xd0\xbe\xd0\xb2\xd0\xbd\xd1\x8b\xd0\xbc\xd0\xb8 \'\xd1\x81\xd1\x86\xd0\xb5\xd0\xbd\xd0\xb0\xd1\x80\xd0\xb8\xd1\x8f\xd0\xbc\xd0\xb8\' \xd0\xb4\xd0\xbb\xd1\x8f \xd0\xbd\xd0\xb0\xd1\x88\xd0\xb5\xd0\xb3\xd0\xbe \xd0\xb8\xd1\x81\xd1\x81\xd0\xbb\xd0\xb5\xd0\xb4\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd1\x8f. \xd0\x92 \xd1\x80\xd0\xb5\xd0\xb7\xd1\x83\xd0\xbb\xd1\x8c\xd1\x82\xd0\xb0\xd1\x82\xd0\xb5 \xd1\x80\xd0\xb0\xd0\xb7\xd1\x80\xd0\xb0\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb0\xd0\xbd\xd1\x8b \xd0\xbf\xd0\xbe\xd0\xbb\xd0\xbe\xd0\xb6\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f, \xd1\x80\xd0\xb0\xd1\x81\xd1\x81\xd0\xbc\xd0\xb0\xd1\x82\xd1\x80\xd0\xb8\xd0\xb2\xd0\xb0\xd1\x8e\xd1\x89\xd0\xb8\xd0\xb5 \xd1\x82\xd0\xb0\xd0\xba\xd1\x82\xd0\xb8\xd0\xba\xd1\x83 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xbe\xd0\xb9 \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd0\xb8 \xd0\xbf\xd1\x80\xd0\xb8 \xd1\x80\xd0\xb0\xd0\xb7\xd0\xbb\xd0\xb8\xd1\x87\xd0\xbd\xd1\x8b\xd1\x85 \xd0\xbe\xd0\xb1\xd1\x81\xd1\x82\xd1\x80\xd1\x83\xd0\xba\xd1\x82\xd0\xb8\xd0\xb2\xd0\xbd\xd1\x8b\xd1\x85 \xd0\xbf\xd0\xbe\xd1\x80\xd0\xb0\xd0\xb6\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f\xd1\x85 \xd0\xb3\xd0\xbb\xd1\x83\xd0\xb1\xd0\xbe\xd0\xba\xd0\xb8\xd1\x85 \xd0\xb2\xd0\xb5\xd0\xbd. \xd0\xa1\xd0\xbe\xd0\xb3\xd0\xbb\xd0\xb0\xd1\x81\xd0\xbd\xd0\xbe \xd0\xbf\xd1\x80\xd0\xb5\xd0\xb4\xd1\x81\xd1\x82\xd0\xb0\xd0\xb2\xd0\xbb\xd0\xb5\xd0\xbd\xd0\xbd\xd1\x8b\xd0\xbc \xd0\xb4\xd0\xb0\xd0\xbd\xd0\xbd\xd1\x8b\xd0\xbc \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb0\xd0\xb3\xd1\x83\xd0\xbb\xd1\x8f\xd0\xbd\xd1\x82\xd0\xbd\xd0\xb0\xd1\x8f \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd1\x8f \xd0\xbf\xd1\x80\xd0\xb5\xd0\xb4\xd0\xbf\xd0\xbe\xd1\x87\xd1\x82\xd0\xb8\xd1\x82\xd0\xb5\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xb0 \xd0\xbd\xd0\xb0 \xd0\xbf\xd1\x80\xd0\xbe\xd1\x82\xd1\x8f\xd0\xb6\xd0\xb5\xd0\xbd\xd0\xb8\xd0\xb8 6\xe2\x80\x9312 \xd0\xbc\xd0\xb5\xd1\x81\xd1\x8f\xd1\x86\xd0\xb5\xd0\xb2 \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd1\x81\xd1\x82\xd0\xb5\xd0\xbd\xd1\x82\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xbf\xd1\x80\xd0\xb8 \xd0\xbd\xd0\xb5\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xb8\xd1\x85 \xd0\xbf\xd0\xbe\xd1\x80\xd0\xb0\xd0\xb6\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f\xd1\x85 \xd0\xbf\xd0\xbe\xd0\xb4\xd0\xb2\xd0\xb7\xd0\xb4\xd0\xbe\xd1\x88\xd0\xbd\xd1\x8b\xd1\x85 \xd0\xb2\xd0\xb5\xd0\xbd. \xd0\x9d\xd0\xb8\xd0\xb7\xd0\xba\xd0\xbe\xd0\xbc\xd0\xbe\xd0\xbb\xd0\xb5\xd0\xba\xd1\x83\xd0\xbb\xd1\x8f\xd1\x80\xd0\xbd\xd1\x8b\xd0\xb5 \xd0\xb3\xd0\xb5\xd0\xbf\xd0\xb0\xd1\x80\xd0\xb8\xd0\xbd\xd1\x8b \xd1\x8f\xd0\xb2\xd0\xbb\xd1\x8f\xd1\x8e\xd1\x82\xd1\x81\xd1\x8f \xd0\xbc\xd0\xb5\xd1\x82\xd0\xbe\xd0\xb4\xd0\xbe\xd0\xbc \xd0\xb2\xd1\x8b\xd0\xb1\xd0\xbe\xd1\x80\xd0\xb0 \xd0\xb2 \xd0\xbb\xd0\xb5\xd1\x87\xd0\xb5\xd0\xbd\xd0\xb8\xd0\xb8 \xd0\xb2 \xd1\x82\xd0\xb5\xd1\x87\xd0\xb5\xd0\xbd\xd0\xb8\xd0\xb5 \xd0\xbf\xd0\xb5\xd1\x80\xd0\xb2\xd1\x8b\xd1\x85 2\xe2\x80\x936 \xd0\xbd\xd0\xb5\xd0\xb4\xd0\xb5\xd0\xbb\xd1\x8c. \xd0\x9f\xd0\xbe\xd0\xb6\xd0\xb8\xd0\xb7\xd0\xbd\xd0\xb5\xd0\xbd\xd0\xbd\xd0\xbe\xd0\xb5 \xd0\xbf\xd1\x80\xd0\xb8\xd0\xbc\xd0\xb5\xd0\xbd\xd0\xb5\xd0\xbd\xd0\xb8\xd0\xb5 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb0\xd0\xb3\xd1\x83\xd0\xbb\xd1\x8f\xd0\xbd\xd1\x82\xd0\xbe\xd0\xb2 \xd1\x80\xd0\xb5\xd0\xba\xd0\xbe\xd0\xbc\xd0\xb5\xd0\xbd\xd0\xb4\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xbe \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd0\xbc\xd0\xbd\xd0\xbe\xd0\xb6\xd0\xb5\xd1\x81\xd1\x82\xd0\xb2\xd0\xb5\xd0\xbd\xd0\xbd\xd1\x8b\xd1\x85 \xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd0\xb7\xd0\xbe\xd0\xb2 \xd0\xb3\xd0\xbb\xd1\x83\xd0\xb1\xd0\xbe\xd0\xba\xd0\xb8\xd1\x85 \xd0\xb2\xd0\xb5\xd0\xbd. \xd0\x9e\xd1\x82\xd0\xbc\xd0\xb5\xd0\xbd\xd0\xb0 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd0\xba\xd0\xbe\xd0\xb0\xd0\xb3\xd1\x83\xd0\xbb\xd1\x8f\xd0\xbd\xd1\x82\xd0\xbe\xd0\xb2 \xd1\x87\xd0\xb5\xd1\x80\xd0\xb5\xd0\xb7 6\xe2\x80\x9312 \xd0\xbc\xd0\xb5\xd1\x81\xd1\x8f\xd1\x86\xd0\xb5\xd0\xb2 \xd0\xbf\xd0\xbe\xd0\xba\xd0\xb0\xd0\xb7\xd0\xb0\xd0\xbd\xd0\xb0 \xd0\xbf\xd0\xbe\xd1\x81\xd0\xbb\xd0\xb5 \xd0\xb2\xd0\xb5\xd0\xbd\xd0\xbe\xd0\xb7\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd1\x81\xd1\x82\xd0\xb5\xd0\xbd\xd1\x82\xd0\xb8\xd1\x80\xd0\xbe\xd0\xb2\xd0\xb0\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xbf\xd1\x80\xd0\xb8 \xd0\xbe\xd0\xb4\xd0\xbd\xd0\xbe\xd0\xbc \xd1\x8d\xd0\xbf\xd0\xb8\xd0\xb7\xd0\xbe\xd0\xb4\xd0\xb5 \xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd0\xb7\xd0\xb0 \xd0\xb3\xd0\xbb\xd1\x83\xd0\xb1\xd0\xbe\xd0\xba\xd0\xb8\xd1\x85 \xd0\xb2\xd0\xb5\xd0\xbd. \xd0\x9d\xd0\xb5 \xd0\xb4\xd0\xbe\xd1\x81\xd1\x82\xd0\xb8\xd0\xb3\xd0\xbd\xd1\x83\xd1\x82\xd0\xbe \xd1\x81\xd0\xbe\xd0\xb3\xd0\xbb\xd0\xb0\xd1\x88\xd0\xb5\xd0\xbd\xd0\xb8\xd0\xb5 \xd0\xbe\xd1\x82\xd0\xbd\xd0\xbe\xd1\x81\xd0\xb8\xd1\x82\xd0\xb5\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe \xd1\x80\xd0\xbe\xd0\xbb\xd0\xb8 \xd0\xb4\xd0\xbb\xd0\xb8\xd1\x82\xd0\xb5\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd0\xb9 \xd0\xb4\xd0\xb5\xd0\xb7\xd0\xb0\xd0\xb3\xd1\x80\xd0\xb5\xd0\xb3\xd0\xb0\xd0\xbd\xd1\x82\xd0\xbd\xd0\xbe\xd0\xb9 \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd0\xb8. \xd0\x92 \xd1\x81\xd1\x82\xd0\xb0\xd1\x82\xd1\x8c\xd0\xb5 \xd0\xbf\xd0\xbe\xd0\xb4\xd1\x87\xd0\xb5\xd1\x80\xd0\xba\xd0\xb8\xd0\xb2\xd0\xb0\xd0\xb5\xd1\x82\xd1\x81\xd1\x8f \xd0\xb2\xd0\xb0\xd0\xb6\xd0\xbd\xd0\xbe\xd1\x81\xd1\x82\xd1\x8c \xd1\x82\xd1\x89\xd0\xb0\xd1\x82\xd0\xb5\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd0\xb8\xd0\xbd\xd0\xb4\xd0\xb8\xd0\xb2\xd0\xb8\xd0\xb4\xd1\x83\xd0\xb0\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd0\xb3\xd0\xbe \xd0\xbf\xd0\xbe\xd0\xb4\xd1\x85\xd0\xbe\xd0\xb4\xd0\xb0 \xd0\xba \xd0\xb2\xd1\x8b\xd0\xb1\xd0\xbe\xd1\x80\xd1\x83 \xd0\xbe\xd0\xbf\xd1\x82\xd0\xb8\xd0\xbc\xd0\xb0\xd0\xbb\xd1\x8c\xd0\xbd\xd0\xbe\xd0\xb9 \xd1\x81\xd1\x82\xd1\x80\xd0\xb0\xd1\x82\xd0\xb5\xd0\xb3\xd0\xb8\xd0\xb8 \xd0\xb0\xd0\xbd\xd1\x82\xd0\xb8\xd1\x82\xd1\x80\xd0\xbe\xd0\xbc\xd0\xb1\xd0\xbe\xd1\x82\xd0\xb8\xd1\x87\xd0\xb5\xd1\x81\xd0\xba\xd0\xbe\xd0\xb9 \xd1\x82\xd0\xb5\xd1\x80\xd0\xb0\xd0\xbf\xd0\xb8\xd0\xb8 \xd0\xb8 \xd0\xbe\xd0\xbf\xd1\x80\xd0\xb5\xd0\xb4\xd0\xb5\xd0\xbb\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f \xd1\x82\xd0\xb0\xd0\xba\xd1\x82\xd0\xb8\xd0\xba\xd0\xb8 \xd0\xbb\xd0\xb5\xd1\x87\xd0\xb5\xd0\xbd\xd0\xb8\xd1\x8f \xd0\xb2 \xd1\x81\xd0\xbb\xd0\xbe\xd0\xb6\xd0\xbd\xd1\x8b\xd1\x85 \xd1\x81\xd0\xbb\xd1\x83\xd1\x87\xd0\xb0\xd1\x8f\xd1\x85 \xd1\x81\xd0\xbe\xd0\xb2\xd0\xbc\xd0\xb5\xd1\x81\xd1\x82\xd0\xbd\xd0\xbe \xd1\x81 \xd0\xb3\xd0\xb5\xd0\xbc\xd0\xb0\xd1\x82\xd0\xbe\xd0\xbb\xd0\xbe\xd0\xb3\xd0\xbe\xd0\xbc.</AbstractText>\n        </OtherAbstract>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Delphi consensus</Keyword>\n            <Keyword MajorTopicYN="N">direct oral anticoagulants</Keyword>\n            <Keyword MajorTopicYN="N">disaggregants</Keyword>\n            <Keyword MajorTopicYN="N">nonthrombotic lesions</Keyword>\n            <Keyword MajorTopicYN="N">post-thrombotic syndrome</Keyword>\n            <Keyword MajorTopicYN="N">venous stenting</Keyword>\n            <Keyword MajorTopicYN="N">vitamin K antagonists</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>11</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>9</Month>\n                <Day>11</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31503264</ArticleId>\n            <ArticleId IdType="doi">10.33529/ANGID2019302</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Neglen P. Chronic deep venous obstruction: definition, prevalence, diagnosis, management. Phlebology. 2008; 23: 4: 149\xe2\x80\x93157. doi: 10.1258/phleb.2008.008027</Citation>\n            </Reference>\n            <Reference>\n                <Citation>De Graaf R, Arnoldussen C, Wittens CHA. Stenting for chronic venous obstructions a new era. Phlebology. 2013; 28(Suppl 1): 117\xe2\x80\x93122. doi: 10.1177/0268355513476449</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Neglen P. Endovascular reconstruction for chronic iliofemoral vein obstruction. In: Gloviczki P, ed. Handbook of Venous Disorders. Third Edition. London: Hodder Arnold. 2009; 491\xe2\x80\x93502.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Razavi MK, Jaff MR, Larry E. Safety and effectiveness of stent placement for iliofemoral venous outflow obstruction. Systematic review and meta-analysis. Circ. Cardiovasc. Interv. 2015; 8: e002772. doi: 10.1161/CIRCINTERVENTIONS.115.002772</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American heart association. Circulation. 2014; 130: 18: 1636\xe2\x80\x931661. doi: 10.1161/CIR.0000000000000130</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wittens C, Davies AH, Boekgaard N, et al. Management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery. Eur. J. Vasc. Endovasc. Surg. 2015; 49: 6: 678\xe2\x80\x93737. doi: 10.1016/j.ejvs.2015.02.007</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Murphy EH, Raju S. Endovascular treatment of postthrombotic iliofemoral venous obstruction. In: Gloviczki P, ed. Handbook of Venous and Lymphatic Disorders. Fourth Edition. Boca Raton, FL.: CRC Press. 2017; 533\xe2\x80\x93539.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Eijgenraam P, ten Cate H, ten Cate-Hoek AJ. Venous stenting after deep venous thrombosis and antithrombotic therapy: a systematic review. Rev. Vasc. Med. 2014; 2: 3: 88\xe2\x80\x9397. doi: 10.1016/j.rvm.2014.03.001</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Neglen P, Hollis KC, Olivier J, Raju S. Stenting of the venous outflow in chronic venous disease: long-term stent-related outcome, clinical, and hemodynamic results. J. Vasc. Surg. 2007; 46: 5: 979\xe2\x80\x93990.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hartung O, Loundou AD, Barthelemy P, et al. Endovacular management of chronic disabling iliocaval obstructive lesions: long-term results. Eur. J. Vasc. Endovasc. Surg. 2009; 38: 1: 118\xe2\x80\x93124. doi: 10.1016/j.ejvs.2009.03.004</Citation>\n            </Reference>\n            <Reference>\n                <Citation>K\xc3\xb6lbel T, Lindth M, Akesson M, et al. Chronic iliac vein occlusion: midterm results of endovascular recanalization. J. Endovasc. Ther. 2009; 16: 4: 483\xe2\x80\x93491. doi: 10.1583/09-2719.1</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lou WS, Gu JP, He X, et al. Endovascular treatment for iliac vein compression syndrome: a comparison between the presence and absence of secondary thrombosis. Korean J. Radiol. 2009; 10: 2: 135\xe2\x80\x93143. doi: 10.3348/kjr.2009.10.2.135</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Rosales A, Sandboek G, J\xc3\xb8rgensen JJ. Stenting for chronic post-thrombotic vena cava and iliofemoral venous occlusions: mid-term patency and clinical outcome. Eur. J. Vasc. Endovasc. Surg. 2010; 40: 2: 234\xe2\x80\x93240. doi: 10.1016/j.ejvs.2010.04.016</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Alhalbouni S, Hingorani A, Shiferson A, et al. Iliac-femoral venous stenting for lower extremity venous stasis symptoms. Ann. Vasc. Surg. 2012; 26: 2: 185\xe2\x80\x93189. doi: 10.1016/j.avsg.2011.05.033</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kurklinsky AK, Bjarnason H, Friese JL, et al. Outcomes of venoplasty with stent placement for chronic thrombosis of the iliac and femoral veins: single-center experience. J. Vasc. Interv. Radiol. 2012; 23: 8: 1009\xe2\x80\x931015. doi: 10.1016/j.jvir.2012.04.019</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ye K, Lu X, Li W, et al. Long-term outcomes of stent placement for symptomatic nonthrombotic iliac vein lesions in chronic venous disease. J. Vasc. Interv. Radiol. 2012; 23: 4: 497\xe2\x80\x93502. doi: 10.1016/j.jvir.2011.12.021</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sarici IS, Yanar F, Agsaoglu O, et al. Our early experience with iliofemoral vein stenting with postthrombotic syndrome. Phlebology. 2014; 29: 5: 298\xe2\x80\x93303. doi: 10.1177/0268355513477641.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>George R, Verma H, Ram B, Tripathi R. The effect of deep venous stenting on healing of lower limb venous ulcer. Eur. J. Vasc. Endovasc. Surg. 2004; 48: 3: 330\xe2\x80\x93336. doi: 10.1016/j.ejvs.2014.04.031.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Liu Z, Gao N, Shen L, et al. Endovascular treatment for symptomatic iliac vein compression syndrome: a prospective consecutive series of 48 patients. Ann. Vasc. Surg. 2014; 28: 3: 695\xe2\x80\x93704. doi: 10.1016/j.avsg.2013.05.019</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sang H, Li H, Qian A, Qingyou M. Outcome of endovascular treatment in postthrombotic syndrome. Ann. Vasc. Surg. 2014; 28: 6: 1493\xe2\x80\x931500. doi: 10.1016/j.avsg.2014.03.031</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ye K, Lu X, Jiang M, et al. Technical details and clinical outcomes of transpopliteal venous stent placement for postthrombotic chronic total occlusion of the iliofemoral vein. J. Vasc. Interv. Radiol. 2014; 25: 6: 925\xe2\x80\x93932. doi: 10.1016/j.jvir.2014.02.031</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Langwieser N, Bernlochner I, Wustrow I, et al. Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral postthrombotic venous obstruction. Phlebology. 2016; 31: 6: 430\xe2\x80\x93437. doi: 10.1177/0268355515596289</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gwozdz A. Decision-making in the choice of anticoagulants following deep venous stenting. Venous news. 20th October 2017.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Van Vuuren TJ, de Wolf MF, Arnoldussen CP, et al. Editors\xe2\x80\x99 Choice \xe2\x80\x93 Reconstruction of the femoro-ilio-caval outflow by percutaneous and hybrid interventions in symptomatic deep venous obstruction. Eur. J. Vasc. Endovasc. Surg. 2017; 54: 4: 495\xe2\x80\x93503. doi: 10.1016/j.ejvs.2017.06.023</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Thapar A. Identifying practices of antithrombotic therapy post-venous stenting. Venous news. 17th January 2018.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pokrovskii AV, Ignat\'ev IM, Gradusov EV. Rezul\'taty endovaskulyarnogo lecheniya obstruktivnykh porazhenii ven podvzdoshno-bedrennogo segmenta (in Russian). Angiologiya i sosudistaya khirurgiya. 2018; 24: 2: 57\xe2\x80\x9368.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>De Graaf R. Reviewing five years of deep venous stenting: What comes next? Venous news. 10th May 2018.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Milinis K, Thapar A, Shalhoub J, Davies AH. Antithrombotic therapy following venous stenting: International Delphi Consensus. Eur. J. Vasc. Endovasc. Surg. 2018; 55: 4: 537\xe2\x80\x93544. doi: 10.1016/j.ejvs.2018.01.007</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Alonso-Coello P, Bellmunt S, McGorian C, et al. Antithrombotic therapy in peripheral artery disease \xe2\x80\x93 antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb; 141(Suppl 2): e669S\xe2\x80\x93690S. doi: 10.1378/chest.11-2307</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Meissner MH. Indications for platelet inhibitors after venous stents. Phlebology. 2013; 28(Suppl 1): 91\xe2\x80\x9398. doi: 10.1177/0268355513476828</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'